PeptideDB

DOTA Zoledronate

CAS: 1908409-18-6 F: C23H41N7O14P2 W: 701.56

DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases.
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1].
Invitro DOTA-Zoledronate is a promising agent for the development of other future-oriented radionuclide therapy concepts for personalized nuclear oncology[1].
Name DOTA Zoledronate
CAS 1908409-18-6
Formula C23H41N7O14P2
Molar Mass 701.56
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. The ITM Group Announces In-Licensing of DOTA-Zoledronate Theranostic Agent.